The Board of Directors of Affymax, Inc. (OTCPK:AFFY) is reviewing its strategic options as a result of the termination of the collaboration with Takeda Pharmaceutical Company Limited (TSE:4502). Affymax and Takeda would terminate their Omontys product partnership in September. The firms would also withdraw their new drug application with the U.S. Food and Drug Administration.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00075 USD | 0.00% | 0.00% | +33.33% |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 55.87K | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.00% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- AFFY Stock
- News Affymax, Inc.
- Affymax To Review Strategic Options